NONALCOHOLIC STEATOHEPATITIS (NASH): IS LEPTIN AN ETIOLOGICAL FACTOR (PHASE 1)
NONALCOHOLIC STEATOHEPATITIS (NASH): IS LEPTIN AN ETIOLOGICAL FACTOR (PHASE 1)
批准号:
7603752
负责人:
Elif Arioglu Oral
金额:
$0.07万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-03-01 至 2007-09-16
关键词:
AdipocytesAffectBloodBlood Chemical AnalysisBody CompositionBody fatCellsCessation of lifeCicatrixComputer Retrieval of Information on Scientific Projects DatabaseConditionFatty acid glycerol estersFundingGrantHormonesHourImageInstitutionInsulinInsulin ResistanceKnowledgeLeadLeptinLiverLiver FailureOverweightPatientsPhasePlayProcessResearchResearch PersonnelResourcesRoleSourceTestingUnited States National Institutes of HealthVariantWorkdaynonalcoholic steatohepatitispreventresearch studysugar
中文摘要
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
超重会削弱胰岛素荷尔蒙的作用,胰岛素荷尔蒙是控制体内血糖水平的主要荷尔蒙。这被称为胰岛素抵抗状态。胰岛素抵抗通常见于肝脏脂肪积聚的患者。大约10%的肝脏脂肪积聚的患者会出现疤痕,这可能会导致肝功能衰竭和死亡。研究表明,另一个在防止肝脏脂肪堆积方面发挥作用的因素是瘦素激素,这是一种由脂肪细胞分泌的激素。在此之前,我们观察到一组异常体脂患者的瘦素激素浓度非常低。在这组患者中,肝脏有显著的脂肪积聚和瘢痕形成,以及非常严重的胰岛素抵抗。当我们使用瘦素激素时,肝脏问题和胰岛素抵抗都显著逆转,并在大约4个月的时间里使这些患者的瘦素水平接近正常。这些结果让我们想知道瘦素激素是否在其他患有这种疾病的患者的脂肪堆积和疤痕形成过程中发挥作用。然而,关于瘦素激素水平和身体成分的变化以及它们如何相互联系和胰岛素抵抗的知识还很缺乏。在这项研究中,我们想要确定已知的肝脏脂肪积聚和瘢痕形成的患者的体脂分布和血液化学的变化。我们还想知道这些患者的血液化学和体脂分布如何影响循环中的瘦素浓度。这项研究包括一天的测试,包括基线血液工作,有助于确定体内脂肪分布的成像研究,以及持续三个小时的测试,以确定胰岛素在细胞中的有效作用。我们将对50名已知脂肪堆积和疤痕形成的患者进行这些研究。我们将利用这些信息来确定我们是否可以开发新的疗法来逆转或减缓肝脏中的脂肪堆积和疤痕形成。
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Being overweight impairs the action of the insulin hormone, the primary hormone responsible from controlling sugar levels in the body. This is called a state of insulin resistance. Insulin resistance is commonly seen in patients who have fat accumulation in their liver. About 10% of patients with fat accumulation in their liver develop scarring that can lead to failure of liver and death. Another factor that has been shown in research studies to play a role in preventing fat accumulation in the liver is the leptin hormone, a hormone secreted by the fat cells. Previously we have observed very low leptin hormone concentrations in an unusual group of patients with abnormal body fat. In this group, there was marked fat accumulation and scarring in the liver as well as very severe insulin resistance. Both the liver problem and the insulin resistance remarkably reversed when we administered leptin hormone and achieved near normal leptin levels in these patients for about 4 months. These results made us wonder whether leptin hormone plays a role in the fat accumulation and scarring process in other patients with this condition. However, knowledge about the variation of leptin hormone levels and body composition and how these relate to each other and insulin resistance is lacking. In this study, we would like to determine the variation in body fat distribution and blood chemistry in patients known to have fat accumulation and scarring in their liver. We also would like to know how blood chemistry and body fat distribution in these patients affect the circulating leptin concentrations. This study comprises of one day of testing that involves baseline blood work, imaging studies that help to determine body fat distribution and a test that lasts three hours to determine how effective insulin is working in the cells. We will perform these studies on 50 patients with known fat accumulation and scarring. We will use this information to determine if we can develop new therapies to reverse or slow down fat accumulation and scarring in the liver.'
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Probing the relevance of the "counter-inflammatory" noncanonical IkB kinases in r
-
批准号:8735137
-
项目类别:
-
资助金额:$19.16万
-
财政年份:2013
-
负责人:Elif Arioglu Oral
-
依托单位:
Probing the relevance of the "counter-inflammatory" noncanonical IkB kinases in r
-
批准号:8636693
-
项目类别:
-
资助金额:$22.37万
-
财政年份:2013
-
负责人:Elif Arioglu Oral
-
依托单位:
NONALCOHOLIC STEATOHEPATITIS (NASH): IS LEPTIN AN ETIOLOGICAL FACTOR (PHASE2)
-
批准号:7603811
-
项目类别:
-
资助金额:$0.16万
-
财政年份:2007
-
负责人:Elif Arioglu Oral
-
依托单位:
RECOMBINANT LEPTIN THERAPY FOR TREATMENT OF NASH
-
批准号:7216227
-
项目类别:
-
资助金额:$14.76万
-
财政年份:2006
-
负责人:Elif Arioglu Oral
-
依托单位:
NONALCOHOLIC STEATOHEPATITIS (NASH): IS LEPTIN AN ETIOLOGICAL FACTOR (PHASE 1)
-
批准号:7376578
-
项目类别:
-
资助金额:$0.2万
-
财政年份:2006
-
负责人:Elif Arioglu Oral
-
依托单位:
RECOMBINANT LEPTIN THERAPY FOR TREATMENT OF NASH
-
批准号:7078269
-
项目类别:
-
资助金额:$15.22万
-
财政年份:2006
-
负责人:Elif Arioglu Oral
-
依托单位:
NONALCOHOLIC STEATOHEPATITIS (NASH): IS LEPTIN AN ETIOLOGICAL FACTOR (PHASE 1)
-
批准号:7199909
-
项目类别:
-
资助金额:$1.75万
-
财政年份:2005
-
负责人:Elif Arioglu Oral
-
依托单位:
海外基金